RDB06521 - pREP81-ccdB2

Please review the QC test results indicated by check

icon below as well as clone information before placing your order.

pREP81-ccdB2 (#RDB06521)

S. pombe expression vector with nmt1 (low strength) promoter

Clone info.	S. pombe expression vector with nmt1 (low strength) promoter
Comment	Gateway compatible.
Vector backbone	pREP81 (Plasmid)
Selectable markers	E. coli: Amp^r, Cm^r, ccdB.
Growth remarks	Use DB3.1, ccdB Survival or equivalent to amplify this clone. 30 degC is fine.
Depositor\|Developer	Yoshida, Minoru \| Matsuyama, Akihisa \|

Sequence	RDB06521z.seq

Distribution information

Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.

Ordering forms
Order form [Credit Card Payment] [Bank Transfer Payment] [Example of order form ]
MTA, for use for not-for-profit academic purpose [Word] [Example of MTA ]
Please visit Information of Request for Distribution.[link] For for-profit-research purpose, please contact us.

Terms and conditions for distribution In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, the RECIPIENT must cite the following literature(s). In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, the RECIPIENT must state an acknowledgement to the DEPOSITOR. When the RECIPIENT wishes to sell the BIOLOGICAL RESOURCE and/or its DERIVATIVES on commercial basis, the RECIPIENT must obtain a prior written permission from the DEPOSITOR . When requested by the DEPOSITOR, RIKEN BRC informs the DEPOSITOR on the RECIPIENT's name and his/her affiliation.

Remarks Use Survival2 (Invitrogen) or equivalent to amplify this clone.

提供案内 (日本国内) [open/close]

Ordering forms	Order form [Credit Card Payment] [Bank Transfer Payment] [Example of order form ] MTA, for use for not-for-profit academic purpose [Word] [Example of MTA ] Please visit Information of Request for Distribution.[link] For for-profit-research purpose, please contact us.
Terms and conditions for distribution	In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, the RECIPIENT must cite the following literature(s). In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, the RECIPIENT must state an acknowledgement to the DEPOSITOR. When the RECIPIENT wishes to sell the BIOLOGICAL RESOURCE and/or its DERIVATIVES on commercial basis, the RECIPIENT must obtain a prior written permission from the DEPOSITOR . When requested by the DEPOSITOR, RIKEN BRC informs the DEPOSITOR on the RECIPIENT's name and his/her affiliation.
Remarks	Use Survival2 (Invitrogen) or equivalent to amplify this clone.

必要書類	提供依頼書 [依頼書の記入例 ] 提供同意書 (MTA, 非営利学術目的用)[Word] [MTAの記入例 ] 手続きの概要は、「提供申込みについて[link]」をご覧ください。営利目的利用についてはお問い合わせください。
MTAに書く使用条件	利用者は、研究成果の公表にあたって寄託者の指定する文献の引用と、寄託者への謝辞の表明を必要とする。　利用者が本件リソース又はその派生物の販売を望む場合、書面により、寄託者の事前の承認を得る。　寄託者から要請がある場合、理研ＢＲＣは利用者情報のうち研究責任者の氏名ならびにその所属機関名を寄託者に通知する。
備考	このクローンの増殖にはSurvival2 (Invitrogen) あるいは同等の宿主を使用してください。

Catalog #	Resource name	Shipping form	Fee (non-profit org.)
RDB06521	pREP81-ccdB2	DNA solution

Please review the QC test results indicated by check

icon below as well as clone information before placing your order.

How to cite this biological resource

Materials & Methods section:

The pREP81-ccdB2 was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB06521).

Reference section:

Further references such as user reports and related articles (go to bottom)

QC test results

RIKEN BRC has sequenced portions of this material for quality test.
Please review the QC test results indicated by check icon as well as clone information before placing your order.

Test sheet	RDB12285_A3Jm.pdf

Nucleotide sequence of a portion of this resource (if available).

Primer: nmt1Fw Sequence file: RDB12285_A3Jma.seq
>06521_12285_A3Jm_nmt1Fw_A05_02.ab1 1 TGGATATTTT ATTTAATTCA GGGAAAAACG TAACTCTCGG CTACTGGATG GTTCAGTCAC 61 CCAACGATTA CTGGGGAGAG AAAACAGGGC AAAAGCAAAG CTTAAAGGAA TCCGATTGTC 121 ATTCGGCAAT GTGCAGCGAA ACTAAAAACC GGATAATGGA CCTGTTAATC GAAACATTGA 181 AGATGGAAGA GGAATCCTGG CATATCATCA ATTGAATAAG TTGAATTAAT TATTTCAATC 241 TCATTCTCAC TTTCTGACTT ATAGTCGCTT TGTTAAAGCT AGCGTCGACA GGCCTGGATC 301 CGGATATCAA CAAGTTTGTA CAAAAAAGCT GAACGAGAAA CGTAAAATGA TATAAATATC 361 AATATATTAA ATTAGATTTT GCATAAAAAA CAGACTACAT AATACTGTAA AACACAACAT 421 ATCCAGTCAC TATGGCGGCC GCATTAGGCA CCCCAGGCTT TACACTTTAT GCTTCCGGCT 481 CGTATAATGT GTGGATTTTG AGTTAGGATC CGTCGAGATT TTCAGGAGCT AAGGAAGCTA 541 AAATGGAGAA AAAAATCACT GGATATACCA CCGTTGATAT ATCCCAATGG CATCGTAAAG 601 AACATTTTGA GGCATTTCAG TCAGTTGCTC AATGTACCTA TAACCAGACC GTTCAGCTGG 661 ATATTACGGC CTTTTTA //
Primer: nmt1Rv Sequence file: RDB12285_A3Jmb.seq
>06521_12285_A3Jm_nmt1Rv_B05_05.ab1 1 AGCCGCCGGG GGCTGGAGAT CTCATGATAT CACCACTTTG TACAAGAAAG CTGAACGAGA 61 AACGTAAAAT GATATAAATA TCAATATATT AAATTAGATT TTGCATAAAA AACAGACTAC 121 ATAATACTGT AAAACACAAC ATATCCAGTC ACTATGGTCG ACCTGCAGAC TGGCTGTGTA 181 TAAGGGAGCC TGACATTTAT ATTCCCCAGA ACATCAGGTT AATGGCGTTT TTGATGTCAT 241 TTTCGCGGTG GCTGAGATCA GCCACTTCTT CCCCGATAAC GGAGACCGGC ACACTGGCCA 301 TATCGGTGGT CATCATGCGC CAGCTTTCAT CCCCGATATG CACCACCGGG TAAAGTTCAC 361 GGGAGACTTT ATCTGACAGC AGACGTGCAC TGGCCAGGGG GATCACCATC CGTCGCCCGG 421 GCGTGTCAAT AATATCACTC TGTACATCCA CAAACAGACG ATAACGGCTC TCTCTTTTAT 481 AGGTGTAAAC CTTAAACTGC ATTTCACCAG CCCCTGTTCT CGTCAGCAAA AGAGCCGTTC 541 ATTTCAATAA ACCGGGCGAC CTCAGCCATC CCTTCCTGAT TTTCCGCTTT CCAGCGTTCG 601 GCACGCAGAC GACGGGCTTC ATTCTGCATG GTTGTGCTTA CCAGACCGGA GATATTGACA 661 TCATATATGC CTTGAG //

Please visit Sequencing and PCR primers for primer information.

References

Original, user report and related articles

Resource search

Link

Other resources in our bank

External Database

Reference sequence